Latest news with #MesoblastLimited
Yahoo
07-05-2025
- Business
- Yahoo
Mesoblast Limited's (ASX:MSB) market cap dropped AU$96m last week; Individual investors bore the brunt
Key Insights Significant control over Mesoblast by individual investors implies that the general public has more power to influence management and governance-related decisions 50% of the business is held by the top 8 shareholders Recent purchases by insiders This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. To get a sense of who is truly in control of Mesoblast Limited (ASX:MSB), it is important to understand the ownership structure of the business. The group holding the most number of shares in the company, around 39% to be precise, is individual investors. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn). While insiders who own 37% came under pressure after market cap dropped to AU$2.2b last week,individual investors took the most losses. Let's delve deeper into each type of owner of Mesoblast, beginning with the chart below. View our latest analysis for Mesoblast ASX:MSB Ownership Breakdown May 7th 2025 What Does The Institutional Ownership Tell Us About Mesoblast? Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices. Mesoblast already has institutions on the share registry. Indeed, they own a respectable stake in the company. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Mesoblast, (below). Of course, keep in mind that there are other factors to consider, too. ASX:MSB Earnings and Revenue Growth May 7th 2025 Hedge funds don't have many shares in Mesoblast. Looking at our data, we can see that the largest shareholder is Gregory George with 20% of shares outstanding. Silviu Itescu is the second largest shareholder owning 6.2% of common stock, and Grant George holds about 5.2% of the company stock. Silviu Itescu, who is the second-largest shareholder, also happens to hold the title of Chief Executive Officer. We also observed that the top 8 shareholders account for more than half of the share register, with a few smaller shareholders to balance the interests of the larger ones to a certain extent. Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.
Business Insider
01-05-2025
- Business
- Business Insider
Mesoblast Limited (MEOBF) Receives a Buy from Bell Potter
Bell Potter analyst John Hester maintained a Buy rating on Mesoblast Limited (MEOBF – Research Report) today and set a price target of A$3.40. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. Hester covers the Healthcare sector, focusing on stocks such as Polynovo , Mesoblast Limited, and Telix Pharmaceuticals. According to TipRanks, Hester has an average return of 4.8% and a 50.60% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Mesoblast Limited with a $1.86 average price target. Based on Mesoblast Limited's latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $1.58 million and a GAAP net loss of $23.97 million. In comparison, last year the company earned a revenue of $1.69 million and had a GAAP net loss of $16.27 million Based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of MEOBF in relation to earlier this year.
Yahoo
03-03-2025
- Health
- Yahoo
Ryoncil, the first FDA-approved mesenchymal stromal cell therapy
Regenerative medicine, a rapidly advancing field, can be generally defined as a therapeutic methodology for the repair, regeneration, or replacement of damaged or diseased human cells and tissues. Ryoncil is an allogeneic mesenchymal stromal cell (MSC) therapy indicated for the treatment of acute graft-versus-host disease (aGvHD) for children older than two months, including adolescents and teenagers. aGvHD is a common complication of allogeneic haematopoietic stem cell transplantation (alloHCT) and is a detrimental condition with a high mortality rate. Systemic steroid therapy is generally the first line of treatment for aGvHD. According to a study by Malard and colleagues, which was published in Nature in 2020, approximately 35-50% of patients develop systemic-refractory acute graft-versus-host disease (SR-aGvHD). Furthermore, an optimal second-line therapy has not yet been introduced, highlighting the significant need for researchers to develop a safe and effective novel therapy for patients with SR-aGvHD. Cell therapies are a fundamental aspect of regenerative medicine and consist of the administration of living cellular material into a patient to replace or regenerate damaged tissue for functional restoration. There are a variety of cells used within cell therapy, including embryonic stem cells (ESCs), induced pluripotent stem cells, and MSCs. MSCs are stromal cells that exhibit self-renewal and multipotent properties with the capacity to differentiate along mesenchymal and non-mesenchymal lineages. These include osteoblasts, myocytes, adipocytes, and chondrocytes. MSCs can be isolated from various tissues, including bone marrow, cord cells, and molar cells, and pose fewer ethical concerns compared to those associated with the collection of ESCs. SR-Ryoncil was developed and patented by Osiris Therapeutics, which later sold the intellectual property to Mesoblast Limited to initiate Phase III trials. In a single-arm, multi-centre, Phase III trial in children with SR-aGvHD, 89% of which had a severe form of the disease, 70% of children achieved an overall response by Day 28 of treatment using Ryoncil. This measure predicts the survival rates of patients with aGvHD. According to leading data and analytics company GlobalData's Making a Difference with Regenerative Medicine, 2025 report, allogeneic cell therapies have the potential to reduce manufacturing burdens within the pharmaceutical industry. This is due to their advantageous scalability in comparison to autologous treatments as multiple patients can be treated from a single batch, consequently increasing patient accessibility. However, the usage of allogeneic cell therapies exhibits a variety of challenges. For example, larger batches of allogeneic cells create difficulties in preserving cell consistencies, requiring advanced bioprocessing techniques and intricate machinery. Furthermore, the regulatory landscape for allogeneic cell therapies presents complex procedures due to their relative novelty in comparison to autologous treatments. The multipotent characteristics of MSCs have the potential to expand into multiple clinical developments and fulfil the unmet medical demand of various diseases. As the number of patients with alloHCT increases, the development of novel and alternative means of regenerative therapy becomes increasingly important within the pharmaceutical landscape. This highlights the potential of Ryoncil's immunomodulatory effects for the treatment of SR-aGvHD while simultaneously advancing therapeutic applications for other inflammatory diseases, thus allowing researchers to utilise MSC-based therapy options to ultimately improve patient outcomes. "Ryoncil, the first FDA-approved mesenchymal stromal cell therapy" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Associated Press
24-02-2025
- Business
- Associated Press
Dr. Gregory George MD PhD Joins Mesoblast Board
NEW YORK, Feb. 23, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has appointed Dr. Gregory George MD PhD, Mesoblast's largest shareholder, to its Board of Directors. Dr. George founded and managed the largest privately owned ambulatory surgical center company in the United States, SurgCenter Development. Dr. George brings to the Board his background as a medical scientist with unique operational experience having built a start-up company in the medical field and turning it into a highly-efficient multi-billion-dollar commercial organization. Mesoblast Founder and Chief Executive Dr. Silviu Itescu said, 'Greg's unique operational skills and insights will provide tremendous value as Mesoblast transitions to become an efficient commercial organization.' Commenting on his appointment Dr. George said, 'I invested in Mesoblast because of my conviction in the technology, Dr. Itescu's scientific knowledge, vision, and leadership combined with the ability of mesenchymal stem cells to treat, and possibly cure, a wide array of disease processes. I believe in Mesoblast's potential to create a paradigm shift in health care by blazing a new path forward and making the impossible possible.' Dr. George added, 'I have first-hand knowledge of how innovative treatments for musculoskeletal diseases such as arthritis and back pain can transform patient outcomes and be rapidly incorporated into commercial product offerings of outpatient centers. While our Surgical Center company did not have the advantage of having a unique product with a wide patent portfolio like Mesoblast, we succeeded through operational excellence, good communications, being proactive, and trying to always beat timelines.' Chair Jane Bell welcomed Dr. George to the Board and said, 'Greg brings not only a high conviction in Mesoblast and our therapies but additionally important operational and strategic dimensions to our Board that will facilitate our corporate goal of building a major global commercial biotechnology company.' About Mesoblast Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company's proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process. Mesoblast's RYONCIL® (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA-approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. RYONCIL is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China. About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications are expected to provide commercial protection extending through to at least 2041 in major markets. About Mesoblast manufacturing: The Company's proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see LinkedIn: Mesoblast Limited and Twitter: @Mesoblast Forward-Looking Statements This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblast's preclinical and clinical studies, and Mesoblast's research and development programs; Mesoblast's ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast's ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast's RYONCIL for pediatric SR-aGVHD and any other product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast's product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast's ability to enter into and maintain established strategic collaborations; Mesoblast's ability to establish and maintain intellectual property on its product candidates and Mesoblast's ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblast's expenses, future revenues, capital requirements and its needs for additional financing; Mesoblast's financial performance; developments relating to Mesoblast's competitors and industry; and the pricing and reimbursement of Mesoblast's product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast's actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise. Release authorized by the Chief Executive. For more information, please contact:
Yahoo
27-01-2025
- Business
- Yahoo
Why Mesoblast (MESO) Is Among the Best Australian Stocks to Buy Now?
We recently compiled a list of the . In this article, we are going to take a look at where Mesoblast Limited (NASDAQ:MESO) stands against other best Australian stocks to buy now. According to a report by Vanguard published on January 24, Australia's economy is expected to experience a gradual recovery in 2025, following its slowest growth in 32 years in 2024. The report forecasts an economic growth of 2% year over year by the end of 2025, with trimmed mean inflation, a core measure that excludes items at the extremes, expected to reach 2.5% year over year. However, the report notes that low productivity growth and higher unit labor costs will keep core inflation from falling sustainably to the midpoint of the Reserve Bank of Australia's (RBA) 2%–3% target range until later in 2025. The RBA has left its policy rate target unchanged at 4.35% since December 10, but has softened its language around future policy decisions, noting that it is 'gaining some confidence that inflation is moving sustainably toward the target.' Despite this, Vanguard expects the RBA to remain patient and not initiate rate cuts until the second quarter of 2025, due to a tight labor market. READ ALSO: 12 Most Promising Green Stocks According to Hedge Funds and 10 Worst Performing Energy Stocks in 2024. In an interview on January 19, Lochlan Halloway, Market Strategist at Morningstar Australia, pointed out that the premium to fair value of large-cap stocks in the Australian market is abnormally high, trading at around 20% above fair value. According to Halloway, this is a concern as 20 companies account for about 60% of the ASX 100. In terms of value opportunities, Halloway identified the energy sector, particularly companies that are trading at significant discounts to their fair value. He also noted that small-cap companies, which were largely left behind in the market rally may offer value, although investors need to be judicious in selecting quality companies. Additionally, sectors such as consumer defensives appear close to fair value or even cheap. As the Australian economy gradually recovers in 2025, opportunities lie in undervalued sectors such as energy and consumer defensives, as well as among small-cap companies that have yet to catch up with the broader market rally. A biotechnologist in a lab suit studying a syringe with a mesenchymal lineage cells inside. To compile our list of the 10 best Australian stocks to buy now, we used Finviz and Yahoo stock screeners to identify Australian companies. We then used Insider Monkey's Hedge Fund database to rank 10 stocks according to the largest number of hedge fund holders, as of Q3 2024. The list is sorted in ascending order of hedge fund sentiment. Why do we care about what hedge funds do? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here). Number of Hedge Fund Holdings: 3 Mesoblast Limited (NASDAQ:MESO) is a leading biotechnology company specializing in the development and commercialization of cell therapies for serious and life-threatening inflammatory and degenerative diseases. The company's flagship product, Remestemcel-L (Ryoncil), recently received FDA approval for treating steroid-refractory acute graft-versus-host disease (SR-aGVHD) in patients aged two months and older. With the FDA approval of Remestemcel-L, Mesoblast Limited (NASDAQ:MESO) is poised to enter a critical phase of commercialization. The company has been actively preparing for this launch by hiring a dedicated commercial team, engaging with key opinion leaders in the medical community, and establishing relationships with bone marrow transplant centers. These efforts are aimed at ensuring a rapid and effective market penetration. Mesoblast Limited (NASDAQ:MESO) is also focusing on educating healthcare providers about the benefits and appropriate use of Remestemcel-L, which is expected to be a key factor in driving adoption. The company is leveraging its existing infrastructure and partnerships to facilitate a smooth rollout, with the goal of capturing a significant share of the SR-aGVHD market, which is estimated to have a substantial total addressable market (TAM). Furthermore, Mesoblast Limited (NASDAQ:MESO) is actively expanding the therapeutic applications of Remestemcel-L. The company is currently conducting a phase 3 study in adult patients with SR-aGVHD, which is expected to commence shortly after the pediatric approval. Additionally, Remestemcel-L is being evaluated for its potential to treat inflammatory bowel disease (IBD), a condition that affects millions of people worldwide. Overall MESO ranks 8th on our list of the best Australian stocks to buy now. While we acknowledge the potential of MESO as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MESO but that trades at less than 5 times its earnings, check out our report about the . READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap Disclosure: None. This article is originally published at . Sign in to access your portfolio
